Matt Miksic
Stock Analyst at Barclays
(3.70)
# 755
Out of 5,132 analysts
330
Total ratings
56.69%
Success rate
5.05%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Underweight | $71 → $72 | $70.02 | +2.83% | 10 | Feb 13, 2026 | |
| BAX Baxter International | Maintains: Overweight | $30 → $25 | $19.79 | +26.33% | 24 | Feb 13, 2026 | |
| MDT Medtronic | Reinstates: Overweight | $116 | $99.49 | +16.59% | 24 | Feb 13, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $104 → $100 | $96.45 | +3.68% | 10 | Feb 12, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Overweight | $202 | $175.89 | +14.84% | 2 | Feb 11, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $86 → $87 | $80.34 | +8.29% | 2 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $136 → $124 | $74.73 | +65.93% | 20 | Feb 3, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $169 → $142 | $112.68 | +26.02% | 32 | Feb 2, 2026 | |
| COO The Cooper Companies | Maintains: Overweight | $97 → $98 | $82.99 | +18.09% | 2 | Jan 26, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $686 → $712 | $485.84 | +46.55% | 9 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $75.87 | +37.08% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $242.74 | +12.88% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $3.81 | +214.96% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $58 → $67 | $65.82 | +1.79% | 9 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $13.36 | +102.10% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $197 → $217 | $243.45 | -10.86% | 15 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $18.96 | +190.08% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $114 | $88.09 | +29.41% | 16 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $7.51 | +312.78% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $17.03 | -0.18% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $366.05 | +23.75% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $79.20 | +8.59% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.01 | +246.53% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.30 | +46.85% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.71 | +285.29% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $78.19 | +27.89% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $186.77 | +123.80% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $17.12 | +63.55% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.95 | +417.37% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $1.82 | +26,273.63% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $11.31 | +669.23% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.73 | +570.24% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $10.04 | +139.04% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $5.12 | +75.78% | 1 | Dec 12, 2016 |
DexCom
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $70.02
Upside: +2.83%
Baxter International
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $19.79
Upside: +26.33%
Medtronic
Feb 13, 2026
Reinstates: Overweight
Price Target: $116
Current: $99.49
Upside: +16.59%
Zimmer Biomet Holdings
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $96.45
Upside: +3.68%
Becton, Dickinson and Company
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $175.89
Upside: +14.84%
GE HealthCare Technologies
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $80.34
Upside: +8.29%
Boston Scientific
Feb 3, 2026
Maintains: Overweight
Price Target: $136 → $124
Current: $74.73
Upside: +65.93%
Abbott Laboratories
Feb 2, 2026
Maintains: Overweight
Price Target: $169 → $142
Current: $112.68
Upside: +26.02%
The Cooper Companies
Jan 26, 2026
Maintains: Overweight
Price Target: $97 → $98
Current: $82.99
Upside: +18.09%
Intuitive Surgical
Jan 26, 2026
Maintains: Overweight
Price Target: $686 → $712
Current: $485.84
Upside: +46.55%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $75.87
Upside: +37.08%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $242.74
Upside: +12.88%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $3.81
Upside: +214.96%
Jan 9, 2026
Maintains: Equal-Weight
Price Target: $58 → $67
Current: $65.82
Upside: +1.79%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $13.36
Upside: +102.10%
Dec 30, 2025
Maintains: Equal-Weight
Price Target: $197 → $217
Current: $243.45
Upside: -10.86%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $18.96
Upside: +190.08%
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $88.09
Upside: +29.41%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $7.51
Upside: +312.78%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $17.03
Upside: -0.18%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $366.05
Upside: +23.75%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $79.20
Upside: +8.59%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.01
Upside: +246.53%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.30
Upside: +46.85%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.71
Upside: +285.29%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $78.19
Upside: +27.89%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $186.77
Upside: +123.80%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $17.12
Upside: +63.55%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.95
Upside: +417.37%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $1.82
Upside: +26,273.63%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $11.31
Upside: +669.23%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.73
Upside: +570.24%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $10.04
Upside: +139.04%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $5.12
Upside: +75.78%